NextCure Inc
NXTC4.870USD
-0.020-0.41%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
136.39MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über NextCure Inc Unternehmen
NextCure, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on advancing medicines that treat cancer patients that do not respond to, or have disease progression on, current therapies, through the use of differentiated mechanisms of actions including Antibody-Drug Conjugates (ADCs), antibodies, and proteins. The Company focuses on advancing therapies that leverage its core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. Its product candidates include NC410 and LNCB74. Its Clinical Oncology Programs are NC525 and NC318. Its Pre-Clinical Non-Oncology Programs are NC605 and NC181. NC410 is a LAIR-2 fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers. NCB74 is an ADC that is directed to B7-H4, a clinically validated cancer target.
Unternehmensinformationen
BörsenkürzelNXTC
Name des UnternehmensNextCure Inc
IPO-datumMay 09, 2019
CEOMr. Michael Richman
Anzahl der mitarbeiter43
WertpapierartOrdinary Share
GeschäftsjahresendeMay 09
Addresse9000 Virginia Manor Rd Ste 200
StadtBELTSVILLE
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl20705-4214
Telefon12403994900
Websitehttps://www.nextcure.com/
BörsenkürzelNXTC
IPO-datumMay 09, 2019
CEOMr. Michael Richman
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Michael Richman
Mr. Michael Richman
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
34.69K
+2.46%
Dr. David S. Kabakoff, Ph.D.
Dr. David S. Kabakoff, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.19K
--
Dr. Udayan Guha, M.D., J.D.
Dr. Udayan Guha, M.D., J.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. John G. Houston, Ph.D.
Dr. John G. Houston, Ph.D.
Independent Director
Independent Director
--
--
Dr. Anne Borgman, M.D.
Dr. Anne Borgman, M.D.
Independent Director
Independent Director
--
--
Dr. Elaine V. Jones, Ph.D.
Dr. Elaine V. Jones, Ph.D.
Independent Director
Independent Director
--
--
Mr. Kevin G. Shaw, J.D.
Mr. Kevin G. Shaw, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
--
--
Dr. Timothy Mayer, Ph.D.
Dr. Timothy Mayer, Ph.D.
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Sol Langermann, Ph.D.
Dr. Sol Langermann, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Sourav Kundu, Ph.D.
Dr. Sourav Kundu, Ph.D.
Senior Vice President - Development and Manufacturing
Senior Vice President - Development and Manufacturing
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Michael Richman
Mr. Michael Richman
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
34.69K
+2.46%
Dr. David S. Kabakoff, Ph.D.
Dr. David S. Kabakoff, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.19K
--
Dr. Udayan Guha, M.D., J.D.
Dr. Udayan Guha, M.D., J.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. John G. Houston, Ph.D.
Dr. John G. Houston, Ph.D.
Independent Director
Independent Director
--
--
Dr. Anne Borgman, M.D.
Dr. Anne Borgman, M.D.
Independent Director
Independent Director
--
--
Dr. Elaine V. Jones, Ph.D.
Dr. Elaine V. Jones, Ph.D.
Independent Director
Independent Director
--
--
Umsatzaufteilung
FY2021
FY2020
Keine Daten
Nach RegionUSD
Name
Umsatz
Anteil
United States
0.00
0.00%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Fri, Aug 1
Aktualisiert: Fri, Aug 1
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Sofinnova Investments, Inc
8.32%
Affinity Asset Advisors LLC
7.17%
Pfizer Inc
6.14%
Citi Investment Research (US)
4.42%
OrbiMed Advisors, LLC
3.55%
Other
70.40%
Aktionäre
Aktionäre
Anteil
Sofinnova Investments, Inc
8.32%
Affinity Asset Advisors LLC
7.17%
Pfizer Inc
6.14%
Citi Investment Research (US)
4.42%
OrbiMed Advisors, LLC
3.55%
Other
70.40%
Aktionärstypen
Aktionäre
Anteil
Hedge Fund
11.47%
Investment Advisor/Hedge Fund
9.20%
Venture Capital
8.38%
Corporation
6.14%
Investment Advisor
5.03%
Research Firm
4.42%
Private Equity
3.55%
Individual Investor
1.65%
Family Office
0.12%
Other
50.03%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
90
1.31M
49.02%
-419.80K
2025Q1
93
15.91M
56.72%
-4.70M
2024Q4
99
16.68M
59.57%
-2.91M
2024Q3
113
18.48M
66.07%
-4.88M
2024Q2
115
18.65M
66.68%
-4.54M
2024Q1
124
18.78M
67.32%
-1.96M
2023Q4
131
15.99M
57.34%
-5.33M
2023Q3
145
15.65M
56.21%
-6.81M
2023Q2
152
15.96M
57.33%
-6.41M
2023Q1
194
15.85M
57.06%
-8.98M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Sofinnova Investments, Inc
2.67M
9.53%
--
--
Mar 31, 2025
Affinity Asset Advisors LLC
2.30M
8.21%
--
--
Mar 31, 2025
Pfizer Inc
1.97M
7.03%
+79.00K
+4.18%
Apr 23, 2025
Citi Investment Research (US)
1.42M
5.06%
+30.33K
+2.18%
Mar 31, 2025
OrbiMed Advisors, LLC
1.14M
4.07%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
987.32K
3.52%
--
--
Mar 31, 2025
Cable Car Capital LLC
670.10K
2.39%
+54.22K
+8.80%
Mar 31, 2025
Acadian Asset Management LLC
488.44K
1.74%
--
--
Mar 31, 2025
Renaissance Technologies LLC
479.96K
1.71%
-39.34K
-7.58%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
465.54K
1.66%
-1.10K
-0.24%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
iShares Micro-Cap ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
Anteil0%
Avantis US Small Cap Equity ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
